Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1 study of M4344 alone and with carboplatin in advanced solid tumors
NL-OMON50338Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gartisertib in Nonhematologic neoplasms and cancer (11 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability, Maximum tolerated dose / recommended phase 2 dose and 2 more. Started May 2015; status: active, not recruiting.
02
Drugs
gartisertib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON50338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50338.